Patents by Inventor Monica Dias

Monica Dias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200231940
    Abstract: The present disclosure relates to recombinant viral vectors, to pharmaceutical compositions comprising such recombinant vectors, and to methods for prevention and treatment of osteoarthritis in mammals. In particular, this disclosure provides adeno-associated virus (AAV) vectors capable of expressing, in a host, osteoprotective/chondroprotective bioactive proteins, including hyaluronan synthase 2 (HAS2) and lubricin (PRG4). Methods of production of these AAV are provided, as are methods of treatment of osteoarthritis in mammalian joints, by the long-term gene expression of osteoprotective/chondroprotective proteins, including HAS2 and PRG4, in both synovial and chondrocyte cells.
    Type: Application
    Filed: July 29, 2019
    Publication date: July 23, 2020
    Inventors: Monica DIAS FIGUEIREDO, Sirkka RM KYOSTIO-MOORE, Patricia BERTHELETTE
  • Publication number: 20170198263
    Abstract: The present disclosure relates to recombinant viral vectors, to pharmaceutical compositions comprising such recombinant vectors, and to methods for prevention and treatment of osteoarthritis in mammals. In particular, this disclosure provides adeno-associated virus (AAV) vectors capable of expressing, in a host, osteoprotective/chondroprotective bioactive proteins, including hyaluronan synthase 2 (HAS2) and lubricin (PRG4). Methods of production of these AAV are provided, as are methods of treatment of osteoarthritis in mammalian joints, by the long-term gene expression of osteoprotective/chondroprotective proteins, including HAS2 and PRG4, in both synovial and chondrocyte cells.
    Type: Application
    Filed: January 13, 2017
    Publication date: July 13, 2017
    Applicants: MERIAL INC., GENZYME CORPORATION
    Inventors: Monica Dias Figueiredo, Sirkka RM Kyostio-Moore, Patricia Berthelette
  • Publication number: 20160347829
    Abstract: The present invention encompasses methods and compositions for inhibiting, treating, and preventing dental diseases in human and non-human animals, particularly domesticated companion animals.
    Type: Application
    Filed: May 23, 2016
    Publication date: December 1, 2016
    Applicant: MERIAL INC.
    Inventors: Robert Nordgren, Monica Dias Figueiredo
  • Patent number: 8603503
    Abstract: A biliquid foam includes from 10% to 98% by weight of a non-polar liquid other than a fuel and from 2 to 88% by weight of a continuous phase polar liquid comprising a C1-C4 alcohol, a liquid polyethylene glycol, ethylene glycol or propylene glycol, or mixtures thereof, in an amount of at least 65% by weight, relative to the weight of the continuous phase, wherein the biliquid foam is stabilized with an amount of from 0.05% to 2% by weight based on the total formulation of a surfactant which is selected from castor oil/poly(alkylene glycol) adducts containing from 20 to 50 alkoxy groups, a C8-C24 fatty acid or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: December 10, 2013
    Assignee: Drug Delivery Solutions Limited
    Inventors: Monica Dias, Philip Guffogg, Derek Wheeler, Mark Whitbread-Jordan
  • Publication number: 20060239947
    Abstract: A biliquid foam comprising from 10% to 98% by weight of a non-polar liquid other than a fuel and from 2 to 88% by weight of a continuous phase polar liquid comprising a C1-C4 alcohol, a liquid polyethylene glycol, ethylene glycol or propylene glycol, or mixtures thereof, in an amount of at least 65% by weight, relative to the weight of the continuous phase, wherein the biliquid foam is stabilized with an amount of from 0.05% to 2% by weight based on the total formulation of a surfactant which is selected from castor oil/poly(alkylene glycol) adducts containing from 20 to 50 alkoxy groups, a C8-C24 fatty acid or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof. A stable dispersion having a content of at least 65% by weight with regard to C1-C4 alcohol, liquid polyethylene glycol, ethylene glycol or propylene glycol which dispersion comprises from 1-80% by weight of a biliquid foam and from 99-20% by weight of an aqueous gel.
    Type: Application
    Filed: July 30, 2004
    Publication date: October 26, 2006
    Inventors: Monica Dias, Philip Guffogg, Derek Wheeler, Mark Whitebread-Jordan
  • Publication number: 20060228408
    Abstract: An oral drug delivery system which comprises a biliquid foam comprising: from 1 to 20% by weight of a continuous hydrophilic phase, from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase, the said pharmaceutically acceptable oil having dissolved or dispersed therein a poorly water-soluble drug in an amount of from 0.1 to 20% by weight and the biliquid foam including therein from 0.5 to 10% by weight of a surfactant to enable the formation of a stable biliquid foam, all percentages being based upon the total weight of the formulation.
    Type: Application
    Filed: July 30, 2004
    Publication date: October 12, 2006
    Inventors: William Charman, Monica Dias, Michelle Georgiou, Philip Guffogg, Christopher Porter, Colin Pouton, Fraser Steele, Derek Wheeler